BACKGROUND:Tenofovir alafenamide (TAF), in combination with FTC, was recently approved for PrEP in the United States. The objective of this study was to assess the relationship between tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) in dried blood spots (DBS) with adherence to TAF/FTC. METHODS:TAF-DBS was a randomized, crossover clinical study of TFV-DP in DBS, following directly observed dosing of 33%, 67%, or 100% of daily TAF (25 mg)/FTC (200 mg). Healthy volunteers were randomized to 2 different, 12-week dosing regimens, separated by a 12-week washout. DBS were collected weekly. TFV-DP and FTC-TP were extracted from two 7-mm punches and assayed with LC-MS/MS. RESULTS:Thirty-seven participants (17 female, 7 African American, and 6 Hispanic) were included. TFV-DP exhibited a mean half-life of 20.8 days (95% confidence interval: 19.3 to 21.3). The slope for TFV-DP versus dosing arm was 1.14 (90% confidence interval: 1.07 to 1.21). The mean (SD) TFV-DP after 12 weeks was 657 (186), 1451 (501), and 2381 (601) fmol/2 7-mm punches for the 33%, 67%, and 100% arms. The following adherence interpretations are proposed: <450 fmol/punches, <2 doses/wk; 450-949 fmol/punches, 2-3 doses/wk; 950-1799 fmol/punches, 4-6 doses/wk; and ≥1800 fmol/punches, 7 doses/wk. FTC-TP was quantifiable for 1 week after drug cessation in 50%, 92%, and 100% of participants in the 33%, 67%, and 100% arms, respectively. CONCLUSION:TFV-DP in DBS after TAF/FTC exhibited a long half-life and was linearly associated with dosing, similar to its predecessor tenofovir disoproxil fumarate. FTC-TP was quantifiable for up to 1 week after drug cessation. Together, these moieties provide complementary measures of cumulative adherence and recent dosing for TAF/FTC.
RCT Entities:
BACKGROUND:Tenofovir alafenamide (TAF), in combination with FTC, was recently approved for PrEP in the United States. The objective of this study was to assess the relationship between tenofovir-diphosphate (TFV-DP) and emtricitabine-triphosphate (FTC-TP) in dried blood spots (DBS) with adherence to TAF/FTC. METHODS:TAF-DBS was a randomized, crossover clinical study of TFV-DP in DBS, following directly observed dosing of 33%, 67%, or 100% of daily TAF (25 mg)/FTC (200 mg). Healthy volunteers were randomized to 2 different, 12-week dosing regimens, separated by a 12-week washout. DBS were collected weekly. TFV-DP and FTC-TP were extracted from two 7-mm punches and assayed with LC-MS/MS. RESULTS: Thirty-seven participants (17 female, 7 African American, and 6 Hispanic) were included. TFV-DP exhibited a mean half-life of 20.8 days (95% confidence interval: 19.3 to 21.3). The slope for TFV-DP versus dosing arm was 1.14 (90% confidence interval: 1.07 to 1.21). The mean (SD) TFV-DP after 12 weeks was 657 (186), 1451 (501), and 2381 (601) fmol/2 7-mm punches for the 33%, 67%, and 100% arms. The following adherence interpretations are proposed: <450 fmol/punches, <2 doses/wk; 450-949 fmol/punches, 2-3 doses/wk; 950-1799 fmol/punches, 4-6 doses/wk; and ≥1800 fmol/punches, 7 doses/wk. FTC-TP was quantifiable for 1 week after drug cessation in 50%, 92%, and 100% of participants in the 33%, 67%, and 100% arms, respectively. CONCLUSION:TFV-DP in DBS after TAF/FTC exhibited a long half-life and was linearly associated with dosing, similar to its predecessor tenofovir disoproxil fumarate. FTC-TP was quantifiable for up to 1 week after drug cessation. Together, these moieties provide complementary measures of cumulative adherence and recent dosing for TAF/FTC.
Authors: Jenna L Yager; Kristina M Brooks; Jose R Castillo-Mancilla; Cricket Nemkov; Mary Morrow; Skyler Peterson; Mustafa Ibrahim; Lane Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson Journal: AIDS Date: 2021-12-01 Impact factor: 4.177
Authors: Casey D Xavier Hall; Camille Bundy; James E Foran; Michael E Newcomb; Héctor Carrillo; Celeste Watkins-Hayes; Brian Mustanski Journal: AIDS Behav Date: 2022-07-29
Authors: Connie L Celum; Elizabeth A Bukusi; Linda Gail Bekker; Sinead Delany-Moretlwe; Lara Kidoguchi; Victor Omollo; Elzette Rousseau; Danielle Travill; Jennifer F Morton; Felix Mogaka; Gabrielle O'Malley; Gena Barnabee; Ariane van der Straten; Deborah Donnell; Urvi M Parikh; Lauren Kudrick; Peter L Anderson; Jessica E Haberer; Linxuan Wu; Renee Heffron; Rachel Johnson; Susan Morrison; Jared M Baeten Journal: J Int AIDS Soc Date: 2022-07 Impact factor: 6.707
Authors: Grant B Ellsworth; Leah A Burke; Martin T Wells; Satish Mishra; Matthew Caffrey; David Liddle; Malika Madhava; Curtis O'Neal; Peter L Anderson; Lane Bushman; Lucas Ellison; Josh Stein; Roy M Gulick Journal: J Acquir Immune Defic Syndr Date: 2021-01-01 Impact factor: 3.771
Authors: Jose R Castillo-Mancilla; Johnathan A Edwards; Jaysingh Brijkumar; Mahomed-Yunus Moosa; Yuan Zhao; Igho Ofotokun; Brent A Johnson; Mitchell H Lee; Selvan Pillay; Melendhran Pillay; Pravi Moodley; Daniel R Kuritzkes; Henry Sunpath; Lane R Bushman; Lucas Ellison; Peter L Anderson; Vincent C Marconi Journal: J Int AIDS Soc Date: 2021-12 Impact factor: 5.396
Authors: Kelly A Johnson; Xin Niu; David V Glidden; Jose R Castillo-Mancilla; Jenna Yager; Samantha MaWhinney; Mary Morrow; Hideaki Okochi; Tim R Cressey; Paul K Drain; Monica Gandhi; Peter L Anderson; Matthew A Spinelli Journal: Open Forum Infect Dis Date: 2021-04-17 Impact factor: 4.423
Authors: Mary Morrow; Samantha MaWhinney; Ryan P Coyle; Stacey S Coleman; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Peter L Anderson; Jose R Castillo-Mancilla Journal: AIDS Date: 2021-10-01 Impact factor: 4.632
Authors: James M McMahon; Janie Simmons; Jessica E Haberer; Sharon Mannheimer; Natalie M Leblanc; Leilani Torres; Robert Quiles; Guillermo Aedo; Anabel Javier; Amy Braksmajer; Graham Harriman; Nicole Trabold; Enrique R Pouget; Ann Kurth; Martez D R Smith; Judith Brasch; Eric J Podsiadly; Peter L Anderson Journal: BMJ Open Date: 2021-07-01 Impact factor: 2.692